TABLE 5.
Any respiratory symptoms and use of asthma medication classified according to asthma treatment among subjects with persistent asthma, by asthma control classified according to Global Initiative for Asthma 2006 criteria [29] at follow-up
| All# | Controlled asthma | Partly controlled asthma | Uncontrolled asthma | p-value | |
| Subjects n | 182 | 100 | 58 | 24 | |
| Any respiratory symptoms at follow-up | 164 (90.1) | 88 (88.0) | 52 (89.7) | 24 (100.0) | 0.207 |
| Treatment at follow-up | |||||
| No treatment | 36 (19.8) | 28 (28.0) | 8 (13.8) | 0 (0) | |
| SABA or LABA without ICS | 24 (13.2) | 16 (16.0) | 7 (12.1) | 1 (4.2) | |
| ICS with SABA or LABA periodically | 28 (15.4) | 17 (17.0) | 9 (15.5) | 2 (8.3) | |
| Low-dose ICS without LABA most days per week | 20 (11.0) | 9 (9.0) | 9 (15.5) | 2 (8.3) | |
| Low-dose ICS and LABA most days per week | 17 (9.3) | 7 (7.0) | 5 (8.6) | 5 (20.8) | |
| Medium/high-dose ICS and LABA most days per week | 57 (31.3) | 23 (23.0) | 20 (34.5) | 14 (58.3) | 0.004 |
Data are presented as n (%), unless otherwise stated. SABA: short-acting β2 agonist; LABA: long-acting β2 agonist; ICS: inhaled corticosteroid. #: n=182. Bold values indicate p<0.05.